Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence
Chronic lymphocytic leukemia (CLL) treatment landscape has changed dramatically with the recently developed drugs targeting the B-cell receptor (BCR) signalling pathway. Acalabrutinib, a second generation Bruton tyrosine kinase inhibitor, was approved in 2020 in Russia for the treatment of patients...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
IP Habib O.N.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/41a3b37b22ed456db3bba0765382dbd5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:41a3b37b22ed456db3bba0765382dbd5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:41a3b37b22ed456db3bba0765382dbd52021-11-30T16:55:01ZAcalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence1815-14341815-144210.26442/18151434.2021.2.200957https://doaj.org/article/41a3b37b22ed456db3bba0765382dbd52021-08-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/77940/58528https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Chronic lymphocytic leukemia (CLL) treatment landscape has changed dramatically with the recently developed drugs targeting the B-cell receptor (BCR) signalling pathway. Acalabrutinib, a second generation Bruton tyrosine kinase inhibitor, was approved in 2020 in Russia for the treatment of patients with CLL. Acalabrutinib was developed as a more selective Bruton tyrosine kinase inhibitor then ibrutinib. This drug is aimed at reducing the adverse events that limit the use of ibrutinib, such as atrial fibrillation and bleeding. Phase I/II multicenter studies have demonstrated the efficacy and safety of acalabrutinib monotherapy in untreated CLL patients and in patients with relapsed/refractory CLL and ibrutinib intolerance. Phase III trials, ASCEND and ELEVATE-TN, compared acalabrutinib monotherapy and a combination of acalabrutinib and obinutuzumab versus standard therapies and demonstrated improved efficacy and tolerability of acalabrutinib. A phase III trial comparing acalabrutinib and ibrutinib monotherapy (ELEVATE-RR) is ongoing. The results of this study along with real-life clinical data could determine the place of acalabrutinib in CLL treatment.Andrei A. PetrenkoMaria I. KislovaElena A. DmitrievaEugene A. NikitinIP Habib O.N.articleacalabrutinibibrutinibbruton tyrosine kinase inhibitorstarget agentschronic lymphocytic leukemiaatrial fibrillationbleedingNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 2, Pp 332-338 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
acalabrutinib ibrutinib bruton tyrosine kinase inhibitors target agents chronic lymphocytic leukemia atrial fibrillation bleeding Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
acalabrutinib ibrutinib bruton tyrosine kinase inhibitors target agents chronic lymphocytic leukemia atrial fibrillation bleeding Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Andrei A. Petrenko Maria I. Kislova Elena A. Dmitrieva Eugene A. Nikitin Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence |
| description |
Chronic lymphocytic leukemia (CLL) treatment landscape has changed dramatically with the recently developed drugs targeting the B-cell receptor (BCR) signalling pathway. Acalabrutinib, a second generation Bruton tyrosine kinase inhibitor, was approved in 2020 in Russia for the treatment of patients with CLL. Acalabrutinib was developed as a more selective Bruton tyrosine kinase inhibitor then ibrutinib. This drug is aimed at reducing the adverse events that limit the use of ibrutinib, such as atrial fibrillation and bleeding. Phase I/II multicenter studies have demonstrated the efficacy and safety of acalabrutinib monotherapy in untreated CLL patients and in patients with relapsed/refractory CLL and ibrutinib intolerance. Phase III trials, ASCEND and ELEVATE-TN, compared acalabrutinib monotherapy and a combination of acalabrutinib and obinutuzumab versus standard therapies and demonstrated improved efficacy and tolerability of acalabrutinib. A phase III trial comparing acalabrutinib and ibrutinib monotherapy (ELEVATE-RR) is ongoing. The results of this study along with real-life clinical data could determine the place of acalabrutinib in CLL treatment. |
| format |
article |
| author |
Andrei A. Petrenko Maria I. Kislova Elena A. Dmitrieva Eugene A. Nikitin |
| author_facet |
Andrei A. Petrenko Maria I. Kislova Elena A. Dmitrieva Eugene A. Nikitin |
| author_sort |
Andrei A. Petrenko |
| title |
Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence |
| title_short |
Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence |
| title_full |
Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence |
| title_fullStr |
Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence |
| title_full_unstemmed |
Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence |
| title_sort |
acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence |
| publisher |
IP Habib O.N. |
| publishDate |
2021 |
| url |
https://doaj.org/article/41a3b37b22ed456db3bba0765382dbd5 |
| work_keys_str_mv |
AT andreiapetrenko acalabrutinibinthetreatmentofchroniclymphocyticleukemiaareviewofrecentevidence AT mariaikislova acalabrutinibinthetreatmentofchroniclymphocyticleukemiaareviewofrecentevidence AT elenaadmitrieva acalabrutinibinthetreatmentofchroniclymphocyticleukemiaareviewofrecentevidence AT eugeneanikitin acalabrutinibinthetreatmentofchroniclymphocyticleukemiaareviewofrecentevidence |
| _version_ |
1718406440078540800 |